Insufficient scRNA-seq data for expression of SEMG1 at single-cell level.
Insufficient scRNA-seq data for expression of SEMG1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 93% | 12212.71 | 227 / 245 | 25% | 78.32 | 124 / 502 |
intestine | 26% | 4.14 | 253 / 966 | 33% | 3.08 | 173 / 527 |
peripheral blood | 59% | 13.49 | 544 / 929 | 0% | 0 | 0 / 0 |
bladder | 38% | 555.00 | 8 / 21 | 13% | 2.29 | 68 / 504 |
adrenal gland | 22% | 1.73 | 56 / 258 | 17% | 9.77 | 39 / 230 |
spleen | 37% | 4.53 | 88 / 241 | 0% | 0 | 0 / 0 |
stomach | 9% | 1.43 | 33 / 359 | 27% | 2.58 | 77 / 286 |
kidney | 36% | 2.79 | 32 / 89 | 0% | 0.00 | 1 / 901 |
lung | 25% | 2.23 | 146 / 578 | 6% | 0.69 | 65 / 1155 |
esophagus | 7% | 4.02 | 98 / 1445 | 23% | 2.35 | 43 / 183 |
pancreas | 3% | 0.25 | 11 / 328 | 14% | 0.43 | 25 / 178 |
breast | 13% | 67.49 | 59 / 459 | 1% | 0.04 | 10 / 1118 |
blood vessel | 10% | 0.97 | 132 / 1335 | 0% | 0 | 0 / 0 |
uterus | 7% | 0.54 | 12 / 170 | 1% | 0.09 | 6 / 459 |
liver | 7% | 0.93 | 16 / 226 | 1% | 0.02 | 4 / 406 |
adipose | 8% | 4.74 | 94 / 1204 | 0% | 0 | 0 / 0 |
ovary | 6% | 1.12 | 10 / 180 | 1% | 0.01 | 3 / 430 |
skin | 5% | 1.89 | 92 / 1809 | 1% | 0.03 | 3 / 472 |
muscle | 5% | 0.77 | 42 / 803 | 0% | 0 | 0 / 0 |
thymus | 4% | 0.83 | 27 / 653 | 1% | 0.35 | 5 / 605 |
heart | 5% | 0.40 | 39 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.09 | 2 / 45 |
brain | 3% | 0.23 | 88 / 2642 | 1% | 0.24 | 4 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050817 | Biological process | coagulation |
GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
GO_0031640 | Biological process | killing of cells of another organism |
GO_0007320 | Biological process | insemination |
GO_1901318 | Biological process | negative regulation of flagellated sperm motility |
GO_0048240 | Biological process | sperm capacitation |
GO_0090281 | Biological process | negative regulation of calcium ion import |
GO_1900005 | Biological process | positive regulation of serine-type endopeptidase activity |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0005615 | Cellular component | extracellular space |
GO_0032991 | Cellular component | protein-containing complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | SEMG1 |
Protein name | SEMG1 protein Semenogelin I Semenogelin-1 (Cancer/testis antigen 103) (Semenogelin I) (SGI) [Cleaved into: Alpha-inhibin-92; Alpha-inhibin-31; Seminal basic protein] |
Synonyms | SEMG |
Description | FUNCTION: Predominant protein in semen. It participates in the formation of a gel matrix entrapping the accessory gland secretions and ejaculated spermatozoa. Fragments of semenogelin and/or fragments of the related proteins may contribute to the activation of progressive sperm movements as the gel-forming proteins are fragmented by KLK3/PSA. .; FUNCTION: Alpha-inhibin-92 and alpha-inhibin-31, derived from the proteolytic degradation of semenogelin, inhibit the secretion of pituitary follicle-stimulating hormone. . |
Accessions | Q6Y806 Q6Y808 P04279 ENST00000372781.4 [P04279-1] A0JLP2 |